Home > Healthcare & Medical Devices > Oncology Market
Oncology Market Size exceeded USD 270.5 billion in 2021 and is anticipated to grow at 10.2% CAGR between 2022 and 2028. Rising alcohol and tobacco consumption have led to the rise in global oncology burden. Also, as the industry players lay a strong emphasis on developing novel drug candidates targeting different types of cancers, a steady growth is poised in the market during the forecast period.
Get more details on this report - Request Free Sample PDF
The COVID-19 pandemic has impacted every aspect of oncology care and research, as several countries across the globe have classified screening and oncology care services as a relatively low-priority services. For instance, the government of Scotland temporarily suspended screening programs for cervical, bowel and breast cancers in light of increasing cases of COVID-19 pandemic.
Moreover, several local- and national-level restrictions implemented by public and private authorities on the movement of people and goods is noted to significantly disrupt the pharmaceutical products and ingredients supply chain, thereby hampering the industry growth. Additionally, temporary closure of various academic institutes and challenges in providing post-sales services owing to the pandemic, resulted in the reduced supply of oncology product to end users, thereby hindering with the market expansion.
Report Coverage | Details |
---|---|
Base Year: | 2021 |
Market Size in 2021: | 270,827.5 Million (USD) |
Forecast Period: | 2022 to 2028 |
Forecast Period 2022 to 2028 CAGR: | 10.2% |
2028 Value Projection: | 522,254.8 Million (USD) |
Historical Data for: | 2017 to 2021 |
No. of Pages: | 245 |
Tables, Charts & Figures: | 291 |
Segments covered: | Cancer Diagnostics & Treatment, Cancer type, End-use and Region |
Growth Drivers: |
|
Pitfalls & Challenges: |
|
Get more details on this report - Request Free Sample PDF
Technological advancements and automation have enhanced the accuracy levels of cancer tests and also made them user friendly, thereby fostering the industry expansion. For instance, liquid-based cytology (LBC) tests were developed to overcome difficulties in conventional pap test for cervical cancer screening. Liquid based cytology (LBC) test reduces specimen inadequacy by around 80%, thus allowing further applications in chlamydia, HPV and gonorrhoea testing.
Side effects associated with oncology treatment such as chemotherapy can potentially hinder the growth of global industry. Patients undergoing chemotherapy may suffer from long-term damage to the heart, lungs, kidneys, or reproductive organs. This can occur after the treatment by damaging the healthy cells, thus limiting the industry progression. Moreover, certain types of chemotherapy drugs may cause delayed side effects. Few of the common side effects include hair loss, fatigue, anaemia, infections and easy bruising & bleeding among others, thereby hampering the overall market demand.
The cancer diagnostic segment dominated more than 46.6% of the market share in 2021 led by the rising incidence of cancer coupled with technological advancements. The development of an intelligent surgical knife fulfils the growing demand for minimal invasive technologies. Furthermore, detecting cancer merely with physical exams or biomarker tests is noted to be an onerous task while imaging test is must for conformation.
Get more details on this report - Request Free Sample PDF
Breast cancer segment valued at USD 54.06 billion in 2021 due to the rising obesity, hormonal imbalance, age-related risks and replacement therapy in women, the prevalence of breast cancer increases. Additionally, various government initiatives such as BreastScreen Aotearoa in New Zealand providing free tests to women will further augment the industry value over the forthcoming years.
Hospital segment is expected to register 10.4% growth rate through 2028. High acceptance rates for technologically advanced biopsy and other devices utilized in diagnosis of cancer will increase the number of diagnosis carried out in hospitals, thereby stimulating the industry demand. In addition, the increasing presence of electrosurgical procedures and related minimally invasive surgeries has increased the admissions and adoption of oncology treatment in hospital setting, thereby enhancing the segment progression.
Get more details on this report - Request Free Sample PDF
North America oncology market accounted for 45.8% of revenue share in 2021 driven by the growing geriatric population along with rising incidence of cancer in the region. Furthermore, technological advancement in cancer diagnostic techniques and treatment, favourable R&D activities by industry participants are the few other factors that will favour the regional growth.
Few of the notable companies operating in the market are GE Healthcare, Janssen Diagnostics, LLC (Johnson & Johnson), F. Hoffmann-La Roche, Pfizer, Bayer AG, Merck, Abbott, Thermo Fischer Scientific. These industry leaders implemented various strategies such as mergers and acquisitions, collaborations, new product launch, etc. in order to capture high revenue share in the market.
Market, By Cancer Diagnostics & Treatment
Market, By Cancer Type
Market, By End-use
The above information is provided for the following regions and countries: